Form 4: Neogenomics Executive Vice President, General Counsel, and Business Development Officer Reports Changes in Beneficial Ownership
SEC Form 4
Alicia C. Olivo, EVP, GC & Business Development at Neogenomics, reports the surrender of shares to cover tax obligations related to vesting restricted stock and details holdings of stock options and restricted stock units.
Summary
- On May 1, 2025, Alicia C. Olivo, EVP, GC & Business Development at Neogenomics, surrendered 652 shares of common stock to cover tax obligations related to the vesting of restricted stock.
- Following this transaction, Ms. Olivo directly owns 44,701 shares of Neogenomics common stock.
- The report also details Ms. Olivo's holdings of various stock options and restricted stock units (RSUs) with different exercise prices, grant dates, and vesting schedules.
- These holdings include options to buy common stock at prices ranging from $9.45 to $48.99, and RSUs that will convert into common stock upon vesting.
- The report also mentions performance stock units (PSUs) that may vest based on the achievement of certain share growth and revenue growth goals.
Sentiment
Score: 7
Explanation: The document is a standard regulatory filing, indicating normal business operations and executive compensation practices. The sentiment is neutral to slightly positive as it reflects ongoing alignment of executive interests with shareholder value.
Industry Context
This filing is a routine disclosure related to executive compensation and equity ownership, common in publicly traded companies. It provides transparency into the holdings of key personnel and aligns their interests with those of shareholders.
Comparison to Industry Standards
- Equity compensation is a standard practice across the biotech and diagnostics industries to attract and retain talent.
- Companies like Exact Sciences (EXAS) and Guardant Health (GH) also utilize stock options and RSUs as part of their executive compensation packages.
- The vesting schedules and performance-based components are typical for aligning executive incentives with company performance.
Stakeholder Impact
- Shareholders gain transparency into executive compensation and equity ownership.
- Employees may be impacted by the overall compensation structure and incentives for key personnel.
Key Dates
| Date | Description |
|---|---|
| 09/30/2019 | Ms. Olivo was granted 1,394 stock options. |
| 05/01/2020 | Ms. Olivo was granted 1,024 stock options. |
| 05/01/2021 | Ms. Olivo was granted 516 stock options. |
| 08/01/2021 | Ms. Olivo was granted 1,117 stock options. |
| 05/01/2022 | Ms. Olivo was granted 22,222 stock options. |
| 09/01/2022 | Ms. Olivo was granted 55,332 stock options. |
| 05/11/2023 | Ms. Olivo was granted 36,508 stock options, 19,508 performance stock units, and 19,508 restricted stock units. |
| 01/13/2026 | Vesting date for some Restricted Stock Units. |
| 05/11/2026 | Vesting date for some Performance Stock Units. |
| 09/30/2026 | Expiration date for some Stock Options. |
| 02/23/2024 | Ms. Olivo was granted 42,344 stock options and 25,330 performance stock units. |
| 05/01/2025 | Shares surrendered to NeoGenomics, Inc. for retirement to satisfy the tax obligations in connection with the May 1, 2025 vesting of restricted stock. |
| 02/21/2025 | Ms. Olivo was granted 107,450 stock options and 63,238 restricted stock units. |
| 02/23/2027 | Vesting date for some Performance Stock Units. |
| 05/01/2027 | Expiration date for some Stock Options. |
| 05/01/2028 | Expiration date for some Stock Options. |
| 08/01/2028 | Expiration date for some Stock Options. |
| 05/01/2029 | Expiration date for some Stock Options. |
| 09/01/2029 | Expiration date for some Stock Options. |
| 05/11/2030 | Expiration date for some Stock Options. |
| 02/23/2034 | Expiration date for some Stock Options. |
| 02/21/2035 | Expiration date for some Stock Options. |
| 05/05/2025 | Date of signature for the report. |
Keywords
Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, Performance Stock Units, Neogenomics, NEO, Insider Trading, Executive Compensation, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.